Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. 2009

Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
Bipolar Disorder Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Refractory depression is a highly debilitating mental condition that originates major social and economic burden. About 50% of the patients experience a chronic course of illness and up to 20% show an insufficient response to drug treatments. Electroconvulsive therapy (ECT) is the most effective treatment method in refractory depression, although its mechanism of action is still unknown. Brain-derived neurotrophic factor (BDNF) is decreased in depressive episodes, and increases with antidepressant treatment, being suggested as a biomarker of response to ECT. We report the findings of a study on the effects of ECT on BDNF and clinical outcomes in a group of drug resistant depressive patients before and after ECT. The patients post-ECTs have shown an important improvement of depressive symptomatology on the HDRS (p=0.001), of psychotic features on the BPRS (p=0.001) and of the severity of illness on the CGI (p=0.001). There were no changes in the serum BDNF before and after the ECT treatment (p=0.89). These results do not support the hypothesis that the clinical improvement following ECT is due to changes in the BDNF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004565 Electroconvulsive Therapy Electrically induced CONVULSIONS primarily used in the treatment of severe AFFECTIVE DISORDERS and SCHIZOPHRENIA. Convulsive Therapy, Electric,ECT (Psychotherapy),Electroshock Therapy,Shock Therapy, Electric,Convulsive Therapies, Electric,Electric Convulsive Therapies,Electric Convulsive Therapy,Electric Shock Therapies,Electric Shock Therapy,Electroconvulsive Therapies,Electroshock Therapies,Shock Therapies, Electric,Therapies, Electric Convulsive,Therapies, Electric Shock,Therapies, Electroconvulsive,Therapies, Electroshock,Therapy, Electric Convulsive,Therapy, Electric Shock,Therapy, Electroconvulsive,Therapy, Electroshock
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001714 Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. Affective Psychosis, Bipolar,Bipolar Disorder Type 1,Bipolar Disorder Type 2,Bipolar Mood Disorder,Depression, Bipolar,Manic Depression,Manic Disorder,Manic-Depressive Psychosis,Psychosis, Manic-Depressive,Type 1 Bipolar Disorder,Type 2 Bipolar Disorder,Psychoses, Manic-Depressive,Bipolar Affective Psychosis,Bipolar Depression,Bipolar Disorders,Bipolar Mood Disorders,Depression, Manic,Depressions, Manic,Disorder, Bipolar,Disorder, Bipolar Mood,Disorder, Manic,Manic Depressive Psychosis,Manic Disorders,Mood Disorder, Bipolar,Psychoses, Bipolar Affective,Psychoses, Manic Depressive,Psychosis, Bipolar Affective,Psychosis, Manic Depressive
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
December 2006, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
November 2022, International journal of psychiatry in clinical practice,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
March 2016, Brain research bulletin,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
July 2008, Progress in neuro-psychopharmacology & biological psychiatry,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
May 2009, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
February 2007, European archives of psychiatry and clinical neuroscience,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
June 2011, Progress in neuro-psychopharmacology & biological psychiatry,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
September 2006, Progress in neuro-psychopharmacology & biological psychiatry,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
March 2017, Molecular neurobiology,
Brisa Fernandes, and Clarissa S Gama, and Rafael Massuda, and Mariana Torres, and Daniel Camargo, and Mauricio Kunz, and Paulo Silva Belmonte-de-Abreu, and Flávio Kapczinski, and Marcelo Pio de Almeida Fleck, and Maria Inês Lobato
January 2016, Biology of sex differences,
Copied contents to your clipboard!